<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421496</url>
  </required_header>
  <id_info>
    <org_study_id>INS011-16-082</org_study_id>
    <nct_id>NCT03421496</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of Cannabidiol Oral Solution
      as adjunctive therapy with vigabatrin as initial therapy in treating participants with
      Infantile Spasms. The secondary objectives for this study are to evaluate the continued
      efficacy of Cannabidiol Oral Solution after the 14-day treatment with vigabatrin or
      vigabatrin plus Cannabidiol Oral Solution is complete and to evaluate the safety and
      tolerability of Cannabidiol Oral Solution as adjunctive therapy with vigabatrin as initial
      therapy in treating participants with infantile spasms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Considered Complete Responders</measure>
    <time_frame>Visit 1 ( Days -14 to -1 of Screening Period) up to Visit 4 (Day 13 to Day 14 of Initial Treatment Period)</time_frame>
    <description>Complete response is defined as complete resolution of spasms and hypsarrhythmia confirmed by 24-hour video-electroencephalogram (EEG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with Complete Response During Initial Treatment Period: Percentage of Participants Who Relapse During the Extended Treatment Period</measure>
    <time_frame>Visit 5 (Day 14 of Initial Treatment Period) up to Visit 8 ( Week 13 of Extended Treatment Period)</time_frame>
    <description>Relapse during the extended treatment period will be confirmed by video-EEG following parent report of relapse, and time to relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Resolution of Infantile Spasms</measure>
    <time_frame>Visit 1 ( Days -14 to -1 of Screening Period) up to Visit 4 (Day 13 to Day 14 of Initial Treatment Period)</time_frame>
    <description>Resolution of infantile spasms will be assessed by 24-hour video-EEG on Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Resolution of Hypsarrhythmia</measure>
    <time_frame>Visit 1 ( Days -14 to -1 of Screening Period) up to Visit 4 (Day 13 to Day 14 of Initial Treatment Period)</time_frame>
    <description>Resolution of hypsarrhythmia will be assessed by 24-hour video-EEG on Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Impression of Efficacy and Tolerability of Study Drug Clinical Global Impression- Global Improvement (CGI-I) at Visit 5</measure>
    <time_frame>Visit 5 (Day 14 of Initial Treatment Period)</time_frame>
    <description>Investigators will use the CGI-I scale, which is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Reduction in Spasm-Free Days Between the Initial Treatment Period and Screening Period</measure>
    <time_frame>Visit 1 ( Day -14 to -1 of Screening Period) up to Visit 5 ( Day 14 of Initial Treatment Period)</time_frame>
    <description>Reduction in spasm-free days will be determined by seizure diary entries.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Infantile Spasm</condition>
  <arm_group>
    <arm_group_label>Cannabidiol Oral Solution (CBD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol Oral Solution, 40 milligrams per kilogram per day (mg/kg/day), participants will be dosed approximately every 12 hours with food.
Participants will also be taking vigabatrin, 150 mg/kg/day, divided twice daily with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching CBD placebo, 40 mg/kg/day, participants will be dosed approximately every 12 hours with food.
Participants will also be taking vigabatrin, 150 mg/kg/day, divided twice daily with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol Oral Solution</intervention_name>
    <description>An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).</description>
    <arm_group_label>Cannabidiol Oral Solution (CBD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Powder suspension</description>
    <arm_group_label>Cannabidiol Oral Solution (CBD)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sabril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parent(s)/caregiver(s) fully comprehends and signs the informed consent form,
             understands all study procedures, and can communicate satisfactorily with the
             Investigator and study coordinator, in accordance with applicable laws, regulations,
             and local requirements.

          2. Clinical diagnosis of Infantile Spasms and hypsarrythmia, confirmed by a 9-hour
             video-EEG obtained during screening Period and read by the central reader.

          3. General good health (defined as the absence of any clinically relevant abnormalities
             as determined by the Investigator) based on physical and neurological examinations,
             medical history, and clinical laboratory values completed during the Screening Visit
             (Visit 1).

          4. In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and
             able to comply with the study procedures and visit schedules.

        Exclusion Criteria:

          1. Is considered by the investigator, for any reason (including, but not limited to, the
             risks described as precautions, warnings, and contraindications in the current version
             of the Investigator's Brochure for Cannabidiol Oral Solution) to be an unsuitable
             candidate to receive the study drug.

          2. Known or suspected allergy to cannabidiol.

          3. History of an allergic reaction or a known or suspected sensitivity to any substance
             that is contained in the investigational product formulation.

          4. Use of any cannabidiol/cannabis product within 30 days of study entry.

          5. Patient is diagnosed or suspected of having tuberous sclerosis.

          6. Patient has received treatment with either vigabatrin, ACTH, or high-dose steroids
             previously.

          7. Previous or concomitant therapy with felbamate, clobazam, valproic acid, or the
             ketogenic diet.

          8. Positive drug screen for THC.

          9. Patient currently on any disallowed CYP3A4-related medication listed in Appendix 1
             (phenytoin, fluvoxamine, carbamazepine, and St. John's Wort).

         10. Previously received any investigational drug or device or investigational therapy
             within 30 days before Screening.

         11. Clinically significant abnormal laboratory values, including: liver function tests
             (LFTs) such as albumin, direct bilirubin, total bilirubin, aspartate aminotransferase
             (AST), and alanine aminotransferase (ALT) â‰¥3 times the upper limit of normal (ULN).

         12. The investigator may deem the patient eligible if he or she judges the laboratory
             values to be not clinically significant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>(602) 910-2617</phone>
    <email>InsysCBD@insysrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Research and Innovation | MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>253-403-9348</phone>
      <email>ccanorro@multicare.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

